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Abstract 
Background: Circulating microRNAs may represent novel markers for cardiovascular diseases. We evaluated whether 
circulating miRNAs served as potential biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardio‑
myopathy (HCM).
Methods: Cardiac magnetic resonance imaging with postcontrast T1 mapping was performed to non‑invasively 
quantify diffuse myocardial fibrosis in HCM patients who were classified into two groups (T1 < 470 ms or T1 ≥ 470 ms, 
as likely or unlikely to have diffuse fibrosis, respectively). First, we screened 84 miRNAs using human serum/plasma 
miRNA array on plasma of 8 HCM patients (4/group based on T1 time) and 4 healthy controls. From the results of this 
initial array, 16 miRNAs were selected based on their fold changes and relevance to myocardial fibrosis for further 
validation by Taqman real‑time PCR in 55 HCM patients.
Results: Among the 16 miRNAs, the expression of miR‑96‑5p and miR‑373‑3p was low. The remaining 14 (miR‑
18a‑5p, miR‑146a‑5p, miR‑30d‑5p, miR‑17‑5p, miR‑200a‑3p, miR‑19b‑3p, miR‑21‑5p, miR‑193‑5p, miR‑10b‑5p, miR‑
15a‑5p, miR‑192‑5p, miR‑296‑5p, miR‑29a‑3p, and miR‑133a‑3p) were upregulated in HCM patients with T1 < 470 ms 
compared with those with T1 ≥ 470 ms, and 11 (except miR‑192‑5p, miR‑296‑5p and miR‑133a‑3p) were significantly 
inversely correlated with postcontrast T1 values. Individual miRNA had moderate diagnostic value for diffuse myo‑
cardial fibrosis (AUC: 0.663–0.742), but the diagnostic value was greatly improved (AUC: 0.87) for a combination of 8 
miRNAs. In comparison, circulating markers of collagen turnover did not have predictive values for diffuse myocardial 
fibrosis.
Conclusions: These findings suggest that circulating miRNAs provide attractive candidates as putative biomarkers 
for diffuse myocardial fibrosis in HCM.
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Background
Myocardial fibrosis, a hallmark of various cardiovascu-
lar diseases, contributes to heart failure, arrhythmias 
and sudden death [1, 2]. Hypertrophic cardiomyopathy 
(HCM) is the most common monogenic cardiac disease 
and myocardial fibrosis is a common and early feature of 
HCM [3], associated with the poor prognosis in HCM 
patients [3, 4].
Historically, myocardial fibrosis could only be defini-
tively diagnosed with cardiac biopsies. There are cur-
rently no reliable serological biomarkers to detect 
myocardial fibrosis. Recent studies have introduced car-
diac magnetic resonance imaging (CMR) to noninva-
sively diagnose myocardial fibrosis [5]. Late gadolinium 
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enhancement (LGE) is now an established method to 
identify regional myocardial fibrosis [6], but it is unable 
to detect diffuse myocardial fibrosis [3, 6]. Postcontrast 
myocardial longitudinal relaxation time (T1) mapping 
is an emerging CMR technique to evaluate diffuse myo-
cardial fibrosis [7]. A number of T1 mapping techniques 
have been shown to correlate with histologically-quanti-
fied fibrosis [7, 8]. We and others have reported reduced 
T1 times in several cardiac disease states associated with 
diffuse fibrosis [7, 9–13]. However, contrast-enhanced 
CMR is limited by high cost and low availability, and con-
traindicated in patients with significant renal dysfunction 
and implanted cardiac devices.
MicroRNAs (miRNAs) are short, noncoding RNAs of 
18–25 nucleotides that posttranscriptionally control gene 
expression by inhibiting protein translation or induc-
ing target mRNA destabilization. miRNAs are powerful 
regulators of a wide range of important cellular processes 
and have emerged as dominant players in cardiovascular 
disease [14]. Several miRNAs, particularly, miR-21, miR-
29, miR-30, and miR-133, have been implicated in the 
control of myocardial fibrosis [15, 16]. miRNAs are also 
released by cells into circulation [17]. Recent studies have 
suggested that circulating miRNAs serve as biomark-
ers for cardiovascular diseases such as acute myocardial 
infarct, heart failure, coronary artery disease, and hyper-
tension [18, 19]. However, whether circulating miRNAs 
can serve as potential biomarkers for myocardial fibrosis 
has not been evaluated.
In this project, we quantified diffuse myocardial fibro-
sis using postcontrast T1 mapping time. We aimed to 
study: (1) changes of plasma miRNAs in HCM patients 
with diffuse myocardial fibrosis indicated by lower T1 
times, as compared with patients without diffuse fibrosis 
or healthy controls, (2) the correlations between circulat-
ing miRNA levels and postcontrast myocardial T1 times, 
and diagnostic values of circulating miRNA levels for the 
detection of diffuse fibrosis.
Methods
Study population
We recruited 55 patients referred to the Alfred CMR 
department for the further evaluation of asymmetric sep-
tal hypertrophy (ASH) due to HCM from March 2011 to 
October 2012. ASH was defined as an interventricular 
septum thickness of ≥15  mm with a ratio of septal-to-
lateral ventricular wall thickness of ≥1.3:1.0 as measured 
by echocardiography, and the diagnosis of HCM required 
the absence of any other condition that causes the degree 
of hypertrophy observed [20]. Exclusion criteria included 
previous septal reduction therapy, coronary artery dis-
ease, atrial fibrillation, valvular heart disease, systemic 
hypertension, diabetes mellitus, surgery or trauma within 
previous 6 months, known fibrotic or inflammatory dis-
ease or cancer, and contraindications to CMR, including 
pacemaker and defibrillator implantation, and signifi-
cant renal dysfunction (estimated glomerular filtration 
rate (eGFR) <30  ml/min/1.73  m2). This study complied 
with the Declaration of Helsinki and was approved by 
the Institutional Ethics Committee of Alfred Healthcare. 
Informed consent was obtained from all participants. A 
subset of 8 HCM patients and 4 healthy controls were 
selected for miRNA array and all 55 HCM patients were 
included for Taqman real-time PCR analysis.
CMR
CMR was performed using a clinical 1.5-T scanner (Signa 
HD 1.5-T, GE Healthcare, Waukesha, Wisconsin, USA). 
Volumetric LV analysis was performed using the sum-
mation of disc method with a contiguous short-axis 
steady-state free precession pulse sequence stack. LGE 
was used to identify regional fibrosis using a T1-weighted 
inversion recovery gradient echo technique, while a T1 
mapping sequence was used to non-invasively quantify 
diffuse myocardial fibrosis, as previously described [7, 
21]. A region of interest (ROI) was drawn around the 
entire LV myocardium (excluding papillary muscles) to 
calculate postcontrast myocardial T1 time. In subjects 
with regional fibrosis detected by LGE, these areas were 
excluded from the ROI for the primary analysis of post-
contrast myocardial T1 time. T1 times for ROIs includ-
ing areas of LGE were also calculated. To account for the 
potential effects of glomerular filtration rate, time delay 
postcontrast administration, and contrast agent relaxivity 
on gadolinium pharmacokinetics, corrected values of T1 
times were used to normalize postcontrast myocardial T1 
times to a matched state (time postcontrast administra-
tion = 20 min, eGFR = 90 mL/min per 1.73 m2) [22]. In 
addition, raw postcontrast T1 times of the LV blood pool 
(blood T1 times) were calculated.
Echocardiography
Transthoracic echocardiography with a standard clini-
cal protocol was performed immediately prior to CMR. 
Diastolic function was assessed by a combination of 
mitral inflow pattern (E to A ratio and deceleration time) 
and mitral annular velocities (e′, measured at the septal 
and lateral aspects of the mitral annulus in the apical 
4-chamber view). Additionally, mitral E/e′ (septal, lateral 
and mean) was chosen as an index of LV filling pressure.
Blood sample collection
Blood samples were obtained before CMR and col-
lected into EDTA-tubes by venepuncture. Plasma sam-
ples (10 min centrifugation at 400 g followed by a further 
10 min at 600 g) were stored at −80 °C for RNA isolation 
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(detailed below). Serum was collected from additional tube 
without anticoagulants for measurement of amino terminal 
propeptide of type I and III collagen (PINP and PIIINP) by 
radioimmunoassay at the Alfred Pathology Department.
Isolation of RNA from plasma samples
Total RNA was harvested from plasma with Qiazol lysis 
reagent and miRNeasy mini kit (Qiagen) according to the 
manufacturers’ instructions. 2  ml plasma was aliquoted 
into 5 eppendorf tubes (400  µl/tube). 400  µl plasma 
was mixed with 1 ml Qiazol lysis reagent, incubated for 
5  min, and subsequently mixed with 200  µl cholorform 
for 3 min. After spin, the aqueous phase containing RNA 
was carefully collected and mixed with 100  % ethanol. 
RNA was purified by a miRNeasy mini spin column, and 
eluted by the addition of 30  µl RNase-free water. Con-
centration of RNA was measured by nanodrop, and RNA 
was stored at −80 °C for further processing.
miScript II RT kit and miScript miRNA PCR array
0.5  µg total RNA was reversely transcribed into cDNA 
using the miScript II RT kit (Qiagen, Netherlands). 
Then, cDNA was mixed with miScript SyBR green qPCR 
mastermix (Qiagen). 25 µl of the cocktail was aliquoted 
into each well of 96 well plates containing the pre-dis-
pensed miRNA-specific assays [Human Serum/plasma 
miRNA PCR Array, SABiosciences (Qiagen)]. PCR and 
data analysis was performed on an ABI Prism 7300 sys-
tem (Applied Biosystems, USA). The transcript abun-
dance was expressed as fold change over the value of 
the healthy control group calculated by 2−∆∆Ct method. 
Eight housekeeping genes including miR-39 and U6 were 
used. Since U6 was quite consistent among the three 
groups among eight housekeeping genes, U6 was chosen 
as the reference miRNA for validation study by real-time 
PCR.
Taqman real‑time PCR
To confirm data from miScript miRNA PCR array, we 
measured the expression of several dysregualated miR-
NAs using Taqman real-time PCR (Applied Biosys-
tems). 5 µl RNA (10 ng RNA) was reversely transcribed 
into cDNA using Taqman miRNA reverse transcrip-
tion kit (Applied Biosystems). PCR products were 
then amplified from cDNA samples using the Taqman 
miRNA assay together with Taqman Universal PCR 
master mix (Applied Biosystems). The reaction volume 
was 20  µl. PCR reactions were performed on an ABI 
Prism 7500 system (Applied Biosystems). miRNAs of 
each group were expressed as relative miRNA expres-
sion levels using U6 as a reference value by calculating 
2−∆Ct i.e. 2−Ct (miRNA)−Ct(U6).
Statistical analysis
Data were expressed as mean  ±  SD unless otherwise 
stated. SPSS 17.0 was used for statistical analysis. The nor-
mality of data was tested by Kolmogorov–Smirnov test. Chi 
square test was used to compare discrete variables among 
groups. For miRNA array data, to compare differences 
among 3 groups, one-way ANOVA followed by Tukey mul-
tiple comparison test and Kruskal–Wallis test were used 
for parametic and nonparametic data, respectively. Student 
t test or Mann–Whitney U test was employed for com-
parison between the two subgroups of 55 HCM patients 
when appropriate. Spearman correlation coefficients were 
computed to assess the correlations between postcontrast 
T1 times and miRNAs. Receiver operating characteristic 
(ROC) curve analysis was used to calculate the area under 
the curve (AUC) of individual miRNA for diagnosing dif-
fuse fibrosis. To calculate the predictive value of multiple 
miRNAs for diffuse fibrosis, a logistic regression model 
using backward stepwise (likelihood ratio) method was 
used to calculate predicted probabilities. Skewed data was 
Ln transformed prior to inclusion in the logistic regression 
model. AUC was then calculated using ROC curve analy-
sis performed on predicted probabilities. A difference of 
P < 0.05 (two-sided) was considered statistically significant.
Results
Patient demographics
Patient demographics, CMR and echocardiograph data 
for miRNA array (n =  12) and real-time PCR (n =  55) 
are presented in Tables  1 and 2, respectively. The nor-
mal range of postcontrast myocardial T1 times in 
healthy controls in our previous study was 561 ± 47 ms 
[11], so T1 time (excluding regions of LGE) of 470  ms 
(approximately 2 SD below the mean of control values) 
was chosen to divide the HCM cohort into those likely 
(<470  ms) and unlikely (≥470  ms) to have significant 
diffuse myocardial fibrosis [21]. Postcontrast myocar-
dial T1 times excluding LGE and including LGE were 
shown in Tables  1 and 2. T1 times corrected for GFR 
and time delay postcontrast administration were also 
calculated and shown. There was no significant differ-
ence in raw blood T1 times between groups, effectively 
ruling out contrast kinetics as a confounding factor for 
the observed differences in myocardial T1 time between 
groups. LGE (regional fibrosis) was observed in the 
majority of HCM patients and the mean quantity of LGE 
did not differ significantly between the 2 HCM groups 
(Tables  1, 2). For miRNA array study, lateral and mean 
e′ were significantly lower in HCM patients compared to 
controls. Lateral and mean E/e′ were significantly higher 
in patients with diffuse fibrosis compared to controls. 
As expected, septal thickness and the ratio of septal to 
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lateral wall thickness, were significantly increased in 
both HCM groups compared with controls (Table  1). 
For real-time PCR validation study, the presence of fam-
ily history was significantly higher in patients without 
diffuse fibrosis compared to those with diffuse fibrosis 
(Table  2). For both miRNA array and real-time PCR 
study (Tables 1, 2), there were no significant differences 
in age, gender, BMI, eGFR, heart rate, and blood pres-
sure among groups. HCM groups had normal systolic 
function (LVEF).
Table 1 Subject characteristics for miRNA array
Control T1 ≥ 470 T1 < 470
n 4 4 4
Gender (m/f ) 4/0 3/1 2/2
Age (years) 42 ± 16.3 49.5 ± 5.5 58.3 ± 9.5
Height (cm) 175.8 ± 8.6 172.8 ± 5.9 165.5 ± 11.1
Weight (kg) 77.8 ± 4.1 83.5 ± 20.3 70 ± 6.7
Body mass index (kg/m2) 25.4 ± 3.5 27.8 ± 5.8 25.8 ± 4
Family history of HCM (%) NA 50 % 75 %
Resting heart beat (beats/min) 66.8 ± 9.5 69 ± 11.6 60.5 ± 7.9
Systolic blood pressure (mmHg) 120.4 ± 10.2 129.5 ± 16.6 125.3 ± 11.6
Diastolic blood pressure (mmHg) 73 ± 9.8 77.3 ± 10.8 70 ± 10.9
eGFR (mL/min/1.75 m2) 87.8 ± 6.5 79 ± 10.7 77.3 ± 15
Medications
 β‑blockers NA 25 % 75 %
 Calcium channel blockers NA 25 % 25 %
 Angiotensin convert enzyme inhibitor NA 0 % 0 %
 Angiotensin receptor blockers NA 50 % 0 %†
Echocardiography
 Left atrial volume indexed, ml/m2 34.2 ± 10.2 43.1 ± 10.4 56.9 ± 21.3
 E/A ratio 1.53 ± 0.48 1.16 ± 0.44 1.38 ± 0.51
 Deceleration time (ms) 158.5 ± 15.6 226.8 ± 44.8* 200.3 ± 25.2
 Septal e′ (cm/s) 10 ± 3.6 6.2 ± 2.1 6 ± 2.2
 Lateral e′ (cm/s) 13.3 ± 2.3 7.9 ± 3* 7.8 ± 2.9*
 Mean e′ (cm/s) 11.7 ± 2.9 7 ± 2.5* 6.9 ± 2.3*
 Septal E/e′ 8.6 ± 3.4 11.1 ± 2.8 18.9 ± 8.8
 Lateral E/e′ 6 ± 1.3 9 ± 2.9 14.1 ± 5.9*
 Mean E/e′ 7.3 ± 2.3 10.1 ± 2.9 16.5 ± 7.2*
 Resting LVOT gradient (mmHg) 4.5 ± 1.1 47.8 ± 68.7 51.6 ± 60
CMR
 T1 times (ms), excluding LGE 578.5 ± 42 561.5 ± 31.9 440.3 ± 30.3***,††
 T1 times (ms), including LGE 578.5 ± 42 550.9 ± 44.6 435.3 ± 45.5***,††
 T1 times (ms, corrected values) 567.6 ± 50.6 549.7 ± 34.7 422.4 ± 26.6***,††
 Blood T1 times (ms) 296.0 ± 5.3 300.8 ± 31.7 302.3 ± 18.8
 Septal thickness (mm) 7.75 ± 0.96 18 ± 3.6** 19 ± 3.2**
 Lateral wall thickness (mm) 7.5 ± 1 8.5 ± 1.3 8.3 ± 1.7
 Septal/lateral wall thickness 1.04 ± 0.07 2.12 ± 0.35** 2.35 ± 0.44**
 LV mass index (g/BSA) 55.1 ± 8.9 90.6 ± 30.4 94.0 ± 28.3
 LV ejection fraction (%) 57.5 ± 6.1 69 ± 2.9 67 ± 15.5
 Presence of LGE (%) NA 75 % 75 %
 Quantity of LGE (% of LV) mass NA 2.9 ± 4 10.1 ± 12.2
Data are expressed as mean ± SD
CMR cardiac magnetic resonance, LV left ventricular, LVOT left ventricular outflow tract, LGE late gadolinium enhancement, BSA body surface area, T1 times (corrected 
values): T1 times were normalized to a matched state (time post-contrast administration = 20 min, eGFR = 90 mL/min/1.73 m2) to account for the potential effects of 
glomerular filtration rate, time delay post-contrast administration, and contrast agent relaxivity on gadolinium pharmacokinetics
* P < 0.05, ** P < 0.01, *** P < 0.001, vs. controls, † P < 0.05, †† P < 0.001, vs. T1 ≥ 470 ms
Page 5 of 12Fang et al. J Transl Med  (2015) 13:314 
miRNA PCR array
Human serum/plasma miRNA PCR array was per-
formed to measure 84 miRNAs in plasma samples 
from 8 HCM patients and 4 controls  (Additional 
file  1). Plasma levels of 14 miRNAs significantly dif-
fered among the 3 groups, and these 14 miRNAs also 
significantly increased in patients with diffuse fibro-
sis compared to healthy controls (all >5 folds) (Fig. 1). 
Table 2 Subject characteristics for real-time PCR
Data are expressed as mean ± SD
CMR cardiac magnetic resonance, LV left ventricular, LVOT left ventricular outflow tract, LGE late gadolinium enhancement, BSA body surface area, T1 times (corrected 
values): T1 times were normalized to a matched state (time post-contrast administration = 20 min, eGFR = 90 mL/min/1.73 m2) to account for the potential effects of 
glomerular filtration rate, time delay post-contrast administration, and contrast agent relaxivity on gadolinium pharmacokinetics
* P < 0.05, *** P < 0.001, vs. T1 ≥ 470 ms
T1 ≥ 470 T1 < 470
n 28 27
Gender (m/f ) 22/6 22/5
Age (years) 49.1 ± 14.0 49.9 ± 10.8
Height (cm) 171.3 ± 10.7 174.9 ± 7.9
Weight (kg) 81.8 ± 18.7 88.5 ± 14.7
Body mass index (kg/m2) 27.6 ± 4.5 28.9 ± 4.0
Family history of HCM (%) 35.7 % 11.1 %*
Resting heart beat (beats/min) 63.9 ± 10.5 61.5 ± 16.1
Systolic blood pressure (mmHg) 129.7 ± 17.3 130.8 ± 14.9
Diastolic blood pressure (mmHg) 75.0 ± 9.1 71.6 ± 8.6
eGFR (mL/min/1.75 m2) 83.9 ± 7.6 79.7 ± 13.8
Medications
 β‑blockers 50 % 63 %
 Calcium channel blockers 14.3 % 29.6 %
 Angiotensin convert enzyme inhibitor 10.7 % 22.2 %
 Angiotensin receptor blockers 21.4 % 3.7 %
Echocardiography
 Left atrial volume indexed, ml/m2 48.4 ± 18.2 49.6 ± 13.9
 E/A ratio 1.35 ± 0.63 1.40 ± 0.67
 Deceleration time (ms) 200.0 ± 64.0 226.4 ± 44.0
 Septal e′ (cm/s) 6.5 ± 1.5 5.9 ± 1.7
 Lateral e′ (cm/s) 8.5 ± 1.9 7.6 ± 2.9
 Mean e′ (cm/s) 7.5 ± 1.4 6.7 ± 2.1
 Septal E/e′ 12.5 ± 3.8 14.8 ± 5.9
 Lateral E/e′ 9.8 ± 3.8 12.0 ± 5.1
 Mean E/e′ 11.0 ± 3.4 13.4 ± 5.1
 Resting LVOT gradient (mmHg) 32.8 ± 39.6 49.9 ± 51.0
CMR
 T1 times (ms), excluding LGE 536.3 ± 54.6 441.0 ± 30.0***
 T1 times (ms), including LGE 521.3 ± 66.4 432.3 ± 26.2***
 T1 times (ms, corrected values) 518.7 ± 55.2 423.8 ± 34.1***
 Blood T1 times (ms) 310.7 ± 30.4 296.0 ± 29.3
 Septal thickness (mm) 20.3 ± 5.8 19.1 ± 3.3
 Lateral wall thickness (mm) 8.6 ± 1.8 9.2 ± 1.9
 Septal/lateral wall thickness 2.4 ± 0.7 2.1 ± 0.5
 LV mass index (g/BSA) 92.6 ± 35.0 87.4 ± 22.4
 LV ejection fraction (%) 68.5 ± 7.3 70.8 ± 6.5
 Presence of LGE (%) 85.7 % 81.5 %
 Quantity of LGE (% of LV) mass 5.6 ± 7.5 4.7 ± 6.1
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The upregulation in patients with diffuse fibrosis did 
not reach significance compared to patients without 
diffuse fibrosis except for miR-96-5p due to small 
sample size (n  =  4/group). Furthermore, levels of 
these 14 miRNAs were negatively correlated with 
postcontrast T1 times (9 of them have r  < −0.5, 5 of 
them have r < −0.4, Table 3). These 14 miRNAs were 
further validated in 55 HCM patients. Interestingly, 
miR-29a-3p and miR-133a-3p, known to be involved 
in myocardial fibrosis, were not significantly different 
among 3 groups (Fig. 1). We included miR-29a-3p and 
miR-133a-3p for further validation since their roles in 
myocardial fibrosis are well established. 
Validation of miRNA PCR array by real‑time PCR
We validated the expression of the above 14 miRNAs plus 
miR-29a-3p and miR-133a-3p in all 55 HCM patients by 
Taqman real-time PCR. Of the 14 miRNAs that signifi-
cantly differed among the 3 groups by miRNA array, 12 
miRNAs were confirmed to be significantly upregulated 
in patients with diffuse fibrosis compared with those 
without diffuse fibrosis (Fig.  2). Notably, the expression 
of miR-96-5p and miR-373-3p was very low (data not 
shown). miR-29a-3p and miR-133a-3p were also signifi-
cantly increased in patients with diffuse fibrosis (Fig. 2). 
11 miRNAs were significantly and inversely correlated 
with postcontrast T1 times, but the inverse correlations 
Fig. 1 Change of plasma miRNAs in patients with lower T1 time identified by miRNA array. Serum/plasma miRNA array was performed on RNA 
samples isolated from controls, HCM patients with T1 ≥ 470 ms, and with T1 < 470 ms (n = 4/group). Data were expressed as mean ± SEM. *P < 0.05 
vs. Ctrl, #P < 0.05 vs. T1 ≥ 470 ms
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with T1 times were not significant for miR-192-5p 
(r = 0.246, p = 0.071), miR-296-5p (r = 0.239, p = 0.079) 
and miR-133a-3p (r = −0.208, P = 0.127) (Fig. 3). Circu-
lating miRNA levels were not correlated with the preva-
lence or the mean quantity of regional fibrosis quantified 
by LGE, or basic demographic characteristics (age, gen-
der, BMI, blood pressure, family history of HCM, and left 
ventricular ejection fraction). 
Diagnostic values of plasma miRNAs for detection 
of diffuse myocardial fibrosis
The predictive power of circulating miRNAs to identify dif-
fuse myocardial fibrosis was evaluated by ROC curve analy-
sis. Individual ROCs of 14 miRNAs including miR-29a-3p 
and miR-133-3p showed moderate predictive values for the 
presence of diffuse myocardial fibrosis (AUC ranges from 
0.663 to 0.742, Table 4). We then examined whether a com-
plex of miRNAs had improved predictive values over single 
miRNA for detection of diffuse fibrosis by using logistic 
regression analysis. AUC for combination of all 14 miRNAs 
reached 0.87. To avoid overfitting of the data due to redun-
dancies among 14 miRNAs, a logistic regression model with 
backward stepwise (likelihood ratio) method was employed. 
8 miRNAs (miR-18a-5p, miR-30d-5p, miR-21-5p, miR-
193-5p, miR-10b-5p, miR-15a-5p, miR-296-5p, and miR-
29a-3p) were selected by the model and the AUC for the 
combination of these 8 miRNAs remained 0.87 (Fig. 4). 
Circulating markers of collagen turnover
PINP and PIIINP are markers reflecting the status of col-
lagen turnover. Neither PINP nor PIIINP significantly 
differed between patients with or without diffuse fibrosis 
(Fig. 2). AUC of PINP and PIIINP was 0.588 and 0.540, 
respectively (both P > 0.05).
Discussion
Circulating miRNAs are potential biomarkers for vari-
ous cardiovascular diseases [18, 19]. In the present 
study, we aimed to evaluate whether circulating miR-
NAs can serve as potential biomarkers for myocardial 
fibrosis in HCM patients. CMR postcontrast T1 mapping 
was used to separate HCM patients into 2 subgroups 
(T1 < 470 ms or T1 ≥ 470 ms as likely or unlikely to have 
diffuse myocardial fibrosis, respectively). We identi-
fied 14 miRNAs which significantly differed among the 
3 groups (T1  <  470  ms, T1  ≥  470  ms and controls, 4/
group) using human serum/plasma miRNA array. We 
then validated the above 14 miRNAs plus miR-29a-3p 
and miR-133a-3p (known to be involved in fibrosis) 
using Taqman real-time PCR in 55 HCM patients. Out 
of 16 miRNAs selected, 14 were confirmed to be elevated 
in HCM patients with T1  <  470  ms compared to those 
with T1  ≥  470  ms, while 11 miRNA levels significantly 
and inversely correlated with postcontrast T1 times. Fur-
thermore, individual ROCs of these 14 miRNAs showed 
moderate predictive values for the presence of diffuse 
myocardial fibrosis (AUC ranges from 0.663 to 0.742), 
but a combination of miRNAs has good diagnostic value 
for diffuse myocardial fibrosis with an AUC of 0.87. Our 
results suggest that circulating miRNAs represent a novel 
circulating marker of diffuse myocardial fibrosis.
Myocardial fibrosis is difficult to diagnose noninva-
sively. Recent studies have introduced CMR to noninva-
sively diagnose myocardial fibrosis. However, the use of 
CMR is limited by its high cost and contraindications, 
and low availability of CMR facility and expertise. Circu-
lating miRNAs could be practical and attractive markers 
for myocardial fibrosis since they are easily accessible, 
reliably stable and disease-specific. In the present study, 
we have demonstrated that circulating miRNAs are asso-
ciated with diffuse fibrosis in HCM patients. Previous 
studies have suggested that peripheral collagen markers 
such as PINP and PIIIP may serve as markers for myocar-
dial fibrosis. Circulating collagen I synthesis marker was 
strongly correlated with myocardial fibrosis in hyperten-
sive patients [23], and higher circulating PIIINP concen-
trations were associated with increased cardiovascular 
mortality [24]. However, other studies did not show cor-
relations between collagen markers (PINP, PIIINP) and 
myocardial fibrosis in patients with aortic stenosis [25]. 
Therefore, we were interested to know whether PINP and 
PIIINP are markers for myocardial fibrosis in patients 
with HCM. PINP and PIIINP did not increase in diffuse 
fibrosis with an AUC  =  0.588 and 0.540, respectively. 
Table 3 Correlations between  circulating miRNAs meas-
ured by miRNA array and T1 times
Spearman correlation coefficients were computed to assess the correlations 
between postcontrast T1 times and miRNAs
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So, existing collagen turnover markers cannot be used 
in the diagnosis of diffuse fibrosis in HCM patients. In a 
recently published paper, the authors evaluated the cor-
relation between circulating miRNAs and regional fibro-
sis quantified by LGE in HCM patients, and they found 
that miR-29a significantly correlated with regional fibro-
sis [26]. However, they did not quantified diffuse fibrosis 
in HCM patients. In the current study, we did not find 
significant correlations between miRNAs and regional 
fibrosis. Our study focused on the correlation of miR-
NAs with diffuse fibrosis and we found that 14 miR-
NAs including miR-29a-3p were upregulated in diffuse 
fibrosis. Our group has recently demonstrated that the 
amount of diffuse fibrosis quantified by postcontrast T1 
mapping correlate with invasively demonstrated left ven-
tricular stiffness in cardiac transplant recipients [27]. So, 
in HCM patients with CMR evidence of diffuse fibrosis, 
increased ventricular stiffness could contribute to dias-
tolic heart failure.
Among 14 miRNAs identified in our study, the roles 
of miR-21, miR-29a, miR-30d and miR-133a in myocar-
dial fibrosis are well established. miR-21, one of the most 
widely investigated miRNA, regulates fibroblast sur-
vival and promotes fibrosis through targeting sprouty/
Fig. 2 Validation of expression of miRNAs by Taqman real‑time PCR. Taqman real‑time PCR was performed in 55 HCM patients (n = 28 for 
T1 ≥ 470 ms and n = 27 for T1 < 470 ms) to validate the findings from miRNA array. In addition, circulating markers of collagen turnover, ami‑
noterminal propeptide of type I collagen (PINP) and aminoterminal propeptide of type III collagen (PIIINP) was measured. Data were expressed as 
mean ± SEM. *P < 0.05, **P < 0.01
Page 9 of 12Fang et al. J Transl Med  (2015) 13:314 
ERK pathways [28]. miR-29 is the best characterized 
direct regulator of extracelluar matrix protein synthesis 
[29], while miR-30 and miR-133a target connective tis-
sue growth factor (CTGF) [30]. miR-17-92 cluster (miR-
17, miR-18a, miR-19a, and miR-19b), also target CTGF 
as well as thrombospondin-1 in the context of myocar-
dial fibrosis [31]. miR-192 and miR-200a are involved in 
transforming growth factor (TGF)-β signaling [32, 33]. 
Epithelial-to-mesenchymal transition (EMT) is another 
mechanism mediated by miRNAs in myocardial fibrosis 
and miR-10b, miR-192 and miR-200a have a role in TGF-
β-dependent EMT [32–35]. miR-146a is an important 
regulator of the immune response and inflammation 
[36, 37]. In addition, miR-15a is essential for apoptosis 
[38], while miR-296 has been named an angiomiR [39]. 
However, the role of miR-193 in fibrosis is unclear. Taken 
together, the miRNAs identified in our study are involved 
in myocardial fibrosis through different mechanisms 
such as regulating TGF-β/CTGF signaling pathway, ECM 
proteins, fibroblasts and EMT.
It seems that the elevation of circulating miRNAs in 
HCM patients with myocardial fibrosis is caused by 
its upregulation in the stressed myocardium. HCM 
is characterized by mutations in sarcomeric proteins 
Fig. 3 Correlations between miRNA levels and postcontrast T1 times. miRNA levels by real‑time PCR were significantly and inversely correlated with 
postcontrast T1 times (except miR‑192‑5p, miR‑296‑5p and miR‑133a) in 55 HCM patients
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of cardiomyocytes. Cardiac fibroblasts are activated 
through the interactions between cardiomyocytes and 
cardiac fibroblasts. miR-21 and miR-29a are fibroblast-
enriched, while miR-133a is cardiomyocyte-enriched. 
miR-30d comes from both cardiomyocytes and cardiac 
fibroblasts. Circulating miRNAs may also come from 
other cell types such as endothelial cells and immune 
cells. For example, miR-17-92 cluster are expressed on 
endothelial cells in addition to cardiomyocytes [40], 
and miR-296, miR-10b, miR-192 and miR-15a are also 
expressed on endothelial cells [41]. miR-146a is abundant 
in immune cells in addition to its expression in the heart 
[42] and miR-193 is also expressed on mononuclear cells 
[43]. It is speculated that cardiomyocytes and fibroblasts 
under stress may send signals to other cell types, and 
induce the release of miRNAs from other cells into circu-
lation. In addition, miRNAs are potential players in such 
intercellular communication [19, 44] by directly acting as 
paracrine signals or by modulating downstream intercel-
lular signaling mediators.
Conclusion
We have demonstrated that 14 circulating miRNAs 
are associated with diffuse myocardial fibrosis quan-
tified by postcontrast T1 mapping. Although individ-
ual miRNA has moderate diagnostic value for diffuse 
fibrosis, the diagnostic power is greatly improved 
(AUC: 0.87) for a combination of miRNAs. Thus, cir-
culating miRNAs could be a favourable alternative to 
CMR for assessing diffuse myocardial fibrosis because 
of its convenience, with no contraindications.
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miR‑18a‑5p 0.742 0.002 6.65 70.4 71.4
miR‑146a‑5p 0.737 0.003 50.04 69.6 78.6
miR‑30d‑5p 0.729 0.004 15.19 65.2 84.4
miR‑17‑5p 0.722 0.005 0.16 60.9 71.9
miR‑200a‑3p 0.721 0.005 0.085 60.9 75
miR‑19b‑3p 0.712 0.007 127.38 59.3 78.6
miR‑21‑5p 0.710 0.007 37.18 59.3 82.1
miR‑193‑5p 0.709 0.008 0.11 59.3 82.1
miR‑10b‑5p 0.701 0.010 0.05 60.9 75
miR‑15a‑5p 0.694 0.013 2.88 59.3 71.4
miR‑192‑5p 0.681 0.021 0.72 63 75
miR‑296‑5p 0.681 0.021 0.26 56.5 71.4
miR‑29a‑3p 0.717 0.006 9.31 63 82.1
miR‑133a‑3p 0.663 0.038 1.42 63 78.6
Fig. 4 ROC analysis of the complex of 8 miRNAs (miR‑18a‑5p, miR‑
30d‑5p, miR‑21‑5p, miR‑193‑5p, miR‑10b‑5p, miR‑15a‑5p, miR‑296‑5p, 
and miR‑29a‑3p) was used to predict diffuse fibrosis in HCM patients
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